FDA approves Brintellix for major depressive disorder

The US FDA has approved Brintellix™ (vortioxetine) for the treatment of adults with major depressive disorder (MDD). The announcement was jointly made by Lundbeck and Takeda.

The MDD treatment was discovered by Lundbeck researchers in Copenhagen, Denmark. However, the clinical trial program was conducted jointly by Lundbeck and Takeda.

“We are pleased that the FDA has approved Brintellix for the treatment of MDD, a serious and complex condition. Together with our partner Lundbeck, we have been committed to applying our collective expertise to develop new medicines that may help people with depression.”

Charlie Baum, M.D., vice president and head, U.S.Medical and Scientific Affairs at Takeda.

“Since medications affect everyone differently, it is important to have a variety of treatment options available for patients who suffer from depression.”

Mitchell Mathis, acting director of the Division of Psychiatry Products in the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research, in a statement.


Related news:

Lundbeck, Takeda Win U.S. Approval for Depression Therapy (Bloomberg)

Reference link:

Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder (press release)

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.